146 related articles for article (PubMed ID: 38312049)
1. Evaluation of prostate-specific membrane antigen expression in locally advanced or metastatic breast carcinoma with 68 Ga-PSMA-11 positron-emission tomography/computed tomography imaging for potential theranostics.
Parghane RV; Suralkar T; Nikam D; Basu S
Nucl Med Commun; 2024 Apr; 45(4):329-337. PubMed ID: 38312049
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract][Full Text] [Related]
3. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract][Full Text] [Related]
4. Novel [
Wang R; Jin W; Luo Y; Hong H; Zhao R; Li L; Yan L; Qiao J; Ploessl K; Zhu L; Kung HF
Mol Pharm; 2024 Jul; 21(7):3256-3267. PubMed ID: 38856975
[TBL] [Abstract][Full Text] [Related]
5. [
Rosar F; Burgard C; Larsen E; Khreish F; Marlowe RJ; Schaefer-Schuler A; Maus S; Petto S; Bartholomä M; Ezziddin S
Cancer Imaging; 2024 Feb; 24(1):27. PubMed ID: 38389092
[TBL] [Abstract][Full Text] [Related]
6. Combined
Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
10. Baseline [
Groener D; Schneider S; Baumgarten J; Happel C; Klimek K; Mader N; Nguyen Ngoc C; Wichert J; Mandel P; Tselis N; Grünwald F; Sabet A
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672421
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous, Subcutaneous, and Bilateral Adrenal Gland Metastases in Progressive Prostate Carcinoma: Theranostic Potential of 68 Ga-PSMA-11 PET/CT Imaging and 177 Lu-PSMA-617 Therapy.
Parghane RV; Basu S
Clin Nucl Med; 2024 Jun; 49(6):587-588. PubMed ID: 38557426
[TBL] [Abstract][Full Text] [Related]
13. Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177 Lu-PSMA.
Beheshti M; Vali R; Zarehparvar Moghadam S; Amini H; Hakiminejad M; Divband G
Clin Nucl Med; 2024 Jun; 49(6):e276-e277. PubMed ID: 38537212
[TBL] [Abstract][Full Text] [Related]
14. Radionuclide Therapy With 177 Lu-PSMA in a Patient With Hepatocellular Carcinoma.
Pretet V; Giraudet AL; Vergnaud L; Paquet E; Kryza D
Clin Nucl Med; 2024 Jun; 49(6):584-586. PubMed ID: 38630998
[TBL] [Abstract][Full Text] [Related]
15. Effect of External Cooling on
Yilmaz B; Nisli S; Ergul N; Gursu RU; Acikgoz O; Çermik TF
J Nucl Med; 2019 Oct; 60(10):1388-1393. PubMed ID: 30850503
[TBL] [Abstract][Full Text] [Related]
16. A Hangover Under 177 Lu-PSMA-617 Therapy : A Red Flag for Brain 68 Ga-PSMA-11 PET/MRI?
Poterszman N; Somme L; Bund C; Hutt E; Somme F
Clin Nucl Med; 2024 Jun; 49(6):582-583. PubMed ID: 38389216
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
18. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis.
Adnan A; Basu S
Nucl Med Commun; 2021 May; 42(5):566-574. PubMed ID: 33560718
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to
Adnan A; Basu S
J Nucl Med Technol; 2020 Jun; 48(2):148-153. PubMed ID: 32111660
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
